Publications by authors named "Ines Monge"

Claim this Profile
R
Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia.
Carlos Jiménez-Vicente, Iago Arribas, Helena Pomares, Guillermo Ramil, Sandra Castaño-Diez, Inés Monge

Haematologica· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.
Carlos Jimenez-Vicente, Aina Cardus, Sandra Castaño-Diez, Guillermo Ramil, Sara Garcia-Avila, Ines Monge

Blood Cancer J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.
Marc Brusosa, Sonia Ruiz, Inés Monge, María Teresa Solano, Laura Rosiñol

Ann Hematol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyponatremia induced by post-transplant cyclophosphamide in allogeneic hematopoietic cell transplantation.
Marta Gómez-Hernando, Luis F Quintana, María Suárez-Lledo, Nuria Martínez-Cibrian, Andrea Rivero, Inés Monge

Bone Marrow Transplant· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide.
Daniel N Marco, María Queralt Salas, Gonzalo Gutiérrez-García, Inés Monge, Gisela Riu

Pharmaceuticals (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis